Patients and Methods This analysis included 799 patients randomly assigned to receive chemotherapy alone or with concurrent trastuzumab on N9831. Fluorescence in situ hybridization (FISH) was ...

Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Cell, 2022; DOI: 10.1016/j.ccell.2022.10.009 ...

In high-grade osteosarcoma, prognostic factors at diagnosis are insufficient for stratifying patients into relevant subgroups. Recently, a transcriptomic study developed the G1/G2 gene expression ...

A novel drug, MRT-2359, will be studied in a phase 1/2 trial for patients with MYC-driven cancers. The first patient has been treated in a phase 1/2 clinical trial analyzing the novel drug MRT-2359 in ...

Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in MYC-driven tumor cellsPhase 1/2 clinical trial of MRT-2359 ongoing ...